InflaRx (IFRX) said Wednesday it plans to discontinue further development of vilobelimab for the treatment of pyoderma gangrenosum, a rare and inflammatory skin disease.
An independent data monitoring committee conducting an unblinded interim analysis for a phase 3 trial for vilobelimab recommended that the trial be stopped due to futility, the company said.
InflaRx said it intends to focus its resources on INF904, with phase 2a data readouts in chronic spontaneous urticaria and hidradenitis suppurativa expected this summer.
The company said it is also contemplating additional cost savings and redirection of resources, with a view to extending its existing cash runway
InflaRx shares were down nearly 51% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.